Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Innocan Pharma Corp C.INNO

Alternate Symbol(s):  INNPF

Healthcare
Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of... see more

Recent & Breaking News (CSE:INNO)

Innocan Pharma to Participate in the Luxury Meets CBD Conference on October 20 & 21 in New York

Newsfile October 13, 2022

Innocan Pharma (CSE:INNO) patent application for treatment of psoriasis of the scalp goes national

Jonathon Brown October 6, 2022

Innocan Pharma's Patent Application for Treatment of Psoriasis of the Scalp Reached National Phase

Newsfile October 6, 2022

Innocan Pharma (CSE:INNO) provides operational update

Sabrina Cuthbert September 21, 2022

Innocan Pharma Provides an Operational Update

Newsfile September 21, 2022

Innocan Pharma (CSE:INNO) reports another successful result from a pre-clinical study using LPT CBD Liposomal Delivery Platform

John Ballem  September 9, 2022

Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment

Newsfile September 9, 2022

Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

Newsfile September 6, 2022

Innocan Pharma Announces Q2 2022 Results with 70% Annual Increase in Cash Balance and 70% Increase in Working Capital

Newsfile August 30, 2022

Innocan Pharma (CSE:INNO) reports positive results in pilot pain study using LPT CBD Liposomal Delivery Platform

John Ballem  August 17, 2022

Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

Newsfile August 17, 2022

Innocan Pharma (CSE:INNO) approaches 100 per cent CBD bioavailability for its LPT CBD liposomal delivery platform

Azuka Onwuka August 11, 2022

Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform

Newsfile August 11, 2022

Innocan Pharma (CSE:INNO) files patent application entitled "compositions for treatment of hair loss"

John Ballem  August 5, 2022

Innocan Pharma Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

Newsfile August 5, 2022

Innocan Pharma (CSE:INNO) files PCT patent application for diabetic symptoms

Azuka Onwuka July 29, 2022

Innocan Pharma Files PCT Patent Application for Diabetic Symptoms

Newsfile July 29, 2022

Former Dexcel Pharma Analytical Chemist to Join Innocan Pharma LPT Pharmaceutical R&D Team as it is Moving Forward with the LPT Development

Newsfile July 12, 2022

Innocan Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures On a Dog using LPT: "Since The Last LPT injection, Paco (dog) Has Not Had a Seizure for Over 10 weeks"

Newsfile July 6, 2022

Innocan Reports Successful Preclinical Dog-Trial Results Regarding Pain Management: "It Was as If a New Dog Came into Our Lives"

Newsfile June 24, 2022